Innovative AI tool streamlines clinical trial site identification process.
- PSI uses AI to enhance clinical trial site identification.
- The process time has been reduced from weeks to minutes.
- Arango's contextual data platform powers this innovation.
PSI has announced a significant enhancement in the clinical trial site identification process, reducing the time required from weeks to mere minutes. This advancement is made possible through the implementation of an AI agent, which utilizes the Arango contextual data platform. By effectively automating the site identification process, PSI aims to expedite the overall timeline for clinical trials.
The innovative AI tool allows PSI to quickly analyze and evaluate potential clinical trial sites using contextual data. This means that researchers can now access crucial information more rapidly, improving efficiency in the preparation phase of clinical trials. This development is poised to streamline operations and contribute to faster trial completions.
PSI's AI-powered site identification not only saves time but also enhances the quality of data available for clinical trials. By integrating advanced technology into their processes, PSI is shifting the landscape of how clinical research is managed. Such advancements underline the growing role of AI technology in medical research and development.
